According to the report, one driver in market is growth of pharmaceutical industry in emerging economies.
The global pharmaceutical industry is undergoing a crisis because of the extensive use of generics, declining investments, change in the reimbursement environment, and strict government regulations on product safety and pricing.
Therefore, pharmaceutical players are exploring alternative routes to improve revenue by shifting their focus toward pharma opportunity-rich regions.
These regions are known as "pharmerging" markets owing to their high growth potential, rising GDP, increasing healthcare spending, availability of cost-efficient resources, and continuously evolving regulatory environments.
Key players in this market include Agilent Technologies, PerkinElmer, Shimadzu and Thermo Fisher Scientific.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream